INNOVA CAPTAB LIMITED
₹1,031.10-₹19.60 (-1.9%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹3,945 Cr
- P/E
- 51.8x
- EV / EBITDA
- 34.2x
- Revenue
- ₹958 Cr
- Net margin
- 7.9%
- ROCE
- 11.4%
Price chart
Technical chartScreen technicals →+23.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -11.0%
- 3M
- +6.6%
- 6M
- +37.3%
- 1Y
- +23.8%
- 5Y
- +89.1%
52-week range
Day change -₹19.60 (-1.9%) from ₹1,051 to ₹1,031 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in INNOVACAP, bought on each weekday since 2024.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 18.3%
Concerns1
- Low return on equity of 9.4%
Rule-based from financial data. Not advice.
About the company
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies.
Read moreShow less
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.
- Sector
- Healthcare
- Shares outstanding
- 5.7 Cr shares
- ISIN
- INE0DUT01020
- BSE code
- 544067
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹3,945 Cr
- P/E
- 51.8x
- P/B
- 4.6x
- EV / EBITDA
- 34.2x
- EV / Sales
- 4.7x
- P/S
- 4.6x
- Earnings yield
- 1.9%
- 52-week high
- ₹1,299.35
- 52-week low
- ₹645.40
Profitability
- Operating margin
- 12.7%
- Net margin
- 7.9%
- EBITDA margin
- 13.8%
- ROE
- 9.4%
- ROCE
- 11.4%
- ROA
- 5.9%
- Dividend payout
- 0.0%
- Tax rate
- 27.0%
- Other income, % of PBT
- 9.6%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹958 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.8%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 18.3%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹119 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.2%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 30.9%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 19.4%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹112 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 187.2%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹4.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 70.4%
Solvency and efficiency
- Current ratio
- 3.49
- Debt / Equity
- 0.34
- Debt / Assets
- 0.21
- Debt / EBITDA
- 2.05
- Interest coverage
- 7.86
- Financial leverage
- 1.60
- CFO / Net profit
- 1.65
- Cash / Market cap
- 15.0%
- Cash per share
- ₹103.42
- Asset turnover
- 0.75
- Fixed asset turnover
- 5.27
- Capital intensity
- 0.19
- Debtor days
- 92 days
- Inventory turnover
- 5.37
- Cash conversion cycle
- 49 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹9 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹836 Cr |
| Sales | Operating profit | ₹122 Cr |
| Operating profit | Interest | ₹2 Cr |
| Operating profit | Depreciation | ₹17 Cr |
| Operating profit | Profit before tax | ₹103 Cr |
| Other income | Profit before tax | ₹17 Cr |
| Profit before tax | Tax and other | ₹31 Cr |
| Profit before tax | Net profit | ₹89 Cr |
Revenue and net profit
Revenue grew 10.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹411 Cr | ₹34 Cr |
| FY2022 | ₹785 Cr | ₹66 Cr |
| FY2023 | ₹859 Cr | ₹58 Cr |
| FY2024 | ₹865 Cr | ₹68 Cr |
| FY2025 | ₹958 Cr | ₹89 Cr |
Cash flows
FY2025: ₹20.0 Cr from operations, -₹80.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹42 Cr | ₹22 Cr |
| FY2022 | ₹58 Cr | -₹130 Cr |
| FY2023 | ₹39 Cr | -₹49 Cr |
| FY2024 | ₹112 Cr | -₹360 Cr |
| FY2025 | ₹20 Cr | -₹80 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹958 Cr+10.8%1Y
- Net profit
- ₹89 Cr+30.9%1Y
- Cash from operations
- ₹20 Cr
- Free cash flow
- -₹80 Cr
- Revenue CAGR, 5Y
- 18.3%
- EBITDA CAGR, 5Y
- 18.0%
- Net profit CAGR, 5Y
- 19.4%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹958 Cr | ₹122 Cr | — | ₹89 Cr | ₹20 Cr | -₹80 Cr | 10.9% | +10.8% | +30.9% |
Monthly returns
Month-by-month returns of INNOVACAP across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,365 Cr |
| Equity capital | ₹57 Cr |
| Reserves | ₹756 Cr |
| Borrowings | ₹329 Cr |
| Other liabilities | ₹223 Cr |
| Assets | ₹1,365 Cr |
| Fixed assets | ₹637 Cr |
| Capital work in progress | ₹21 Cr |
| Investments | ₹60 Cr |
| Other assets | ₹647 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
INNOVACAP trades at 51.8x earnings against a peer median of 52.6x.
Not shown (no positive earnings and no EV / Sales): Sun Pharma Advanced Research Company Ltd., Dishman Carbogen Amcis Limited.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| INNOVA CAPTAB LIMITEDINNOVACAPthis company | ₹3,945 Cr | 51.8x | 4.6x | 9.4% | 34.2x |
| Sun Pharma Advanced Research Company Ltd.SPARC | ₹4,415 Cr | — | -12.6x | -312.9% | -11.7x |
| Dishman Carbogen Amcis LimitedDCAL | ₹4,132 Cr | — | 1.0x | -1.9% | 67.5x |
| Artemis Medicare Services LimitedARTEMISMED | ₹4,059 Cr | 42.6x | 4.0x | 10.8% | 32.0x |
| Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,008 Cr | 83.0x | 15.1x | 29.4% | 48.1x |
| RPG Life Sciences LimitedRPGLIFE | ₹3,806 Cr | 34.2x | 6.9x | 23.5% | 27.7x |
| SENORES PHARMACEUTICALS LIMITEDSENORES | ₹3,750 Cr | 307.0x | 5.2x | 0.6% | 545.5x |
| Indraprastha Medical Corporation LtINDRAMEDCO | ₹3,742 Cr | 21.4x | 5.7x | 25.9% | 17.5x |
| Orchid Pharma LimitedORCHPHARMA | ₹3,739 Cr | 51.8x | 2.8x | — | — |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
INNOVACAP since 1 January, against earlier years.
Historical volatility
INNOVACAP's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 13.0% |
| FY2022 | 13.0% |
| FY2023 | 11.0% |
| FY2024 | 13.0% |
| FY2025 | 13.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹958 Cr |
| Costs | |
| Interest | ₹2 Cr |
| Expenses | ₹836 Cr |
| Operating profitOperating Profit | ₹122 Cr |
| Other income and charges | |
| Profit before tax | ₹120 Cr |
| Tax | |
| Net profitNet Profit | ₹89 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,365 Cr |
| Equity capitalEquity Capital | ₹57 Cr |
| Reserves | ₹756 Cr |
| Borrowings | ₹329 Cr |
| Other liabilitiesOther Liabilities | ₹223 Cr |
| AssetsTotal Assets | ₹1,365 Cr |
| Fixed assetsFixed Assets | ₹637 Cr |
| Capital work in progressCWIP | ₹21 Cr |
| Investments | ₹60 Cr |
| Other assetsOther Assets | ₹647 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹20 Cr |
| Investing cash flowCash from Investing Activity | -₹100 Cr |
| Financing cash flowCash from Financing Activity | ₹84 Cr |
| Change in cashNet Cash Flow | ₹4 Cr |
Learn while you research
Academy chapters picked for INNOVA CAPTAB LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 51.8, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read